Plain-English translation of NCT03913117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach to treating early cervical changes caused by a common virus called HPV16. Instead of waiting to see if these changes get worse, researchers are testing whether two experimental vaccines — and — can help your immune system clear the infection and prevent it from progressing to cancer. This is a Phase 1 trial, which means researchers are first checking whether the medication is safe and finding the right dose before testing it more widely.
Most people clear HPV on their own, but some develop persistent infections that can lead to cervical cancer. Current treatment often involves watching and waiting, or procedures that remove affected tissue. This trial exists because researchers want to find a way to help your body's immune system fight the virus directly, before more serious changes develop.
You likely qualify if…
You likely don't qualify if…
You will receive a series of muscle injections over several weeks. Depending on which group you are assigned to, you will either receive different doses of the first vaccine at weeks 0, 4, and 8, or you will receive the first vaccine at weeks 0 and 4, followed by a second vaccine at week 8. Throughout the study, you will have follow-up appointments to check for any side effects and to see how your immune system is responding. The trial involves about 30 people total and will help researchers decide if this approach is safe and what dose works best for a larger future study.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Alabama at Birmingham
Collaborators
Johns Hopkins University
Enrollment target
~30 participants
Started
July 2023
Primary completion
December 2027
Age range
19 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wendy Wu, MS
University of Alabama at Birmingham
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.